JP Morgan Healthcare Conference
Filed with ASX · · 27 pages · English
This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial advice, financial product advice or advice rela
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Australian Patent to be Granted for RECCE Anti-Infectives
- Anti-Infective Research Unit est. at Murdoch Childrens
- Approval to Start Phase I/II Diabetic Foot Ulcer Study
- Anti-Infective Portfolio Update and Webinar details
- Pause in trading
Later from Recce Pharmaceuticals
- A$6.21m Received from R&D Rebate Payments
- Recce Selects CMAX for Phase I/II UTI Clinical Trial
- Corporate Presentation - WI Emergence 2023
- Recce Receives Further A$973,144 R&D Advance
- New Family 4 Patent to be Granted for RECCE Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals